Floatz logo

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine

Gastrointestinal Cancer

National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Gastrointestinal Cancer cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
Irinotecan
Amgen
Phase 2BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
malignant urinary system neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →